Oral Challenge Studies: Purpose, Design and Evaluation
description
Transcript of Oral Challenge Studies: Purpose, Design and Evaluation
![Page 1: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/1.jpg)
Oral Challenge Studies: Purpose, Design and Evaluation
Stefano Luccioli, MD
![Page 2: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/2.jpg)
Goals
• Purpose• Design and conduct
– Selection of subjects & materials– Blinding and dosing protocol– Statistics
• Evaluation and interpretation of data– General issues– Sensitivity of subjects– Clinical response and severity
Overview of oral challenge studies
![Page 3: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/3.jpg)
Purpose of challenge studiesConfirm diagnosis of food allergy
– Gold standard: Double-blind, placebo-controlled food challenge (DBPCFC)
Evaluate tolerance
Evaluate allergenic foods/ingredients for certain subpopulations
![Page 4: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/4.jpg)
Purpose of challenge studiesDetermine minimal eliciting doses
Information on individual sensitivityTherapeutic comparisonsLOEL/NOEL data for establishing thresholds
Insufficient animal model and epidemiological (market experience, case reports) data
Evaluate reaction severity- uncommon Current biomarkers not predictive
![Page 5: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/5.jpg)
Assessment of food ingredientsTraditional Tox models
• Genetic Homogeneity• One ingredient in food• Defined endpoints for
severity• NOEL defined• Reproducible• Dose response
Allergen food challenges• Genetic Heterogeneity• Multiple allergens in food• Multiple endpoints;
severity not well defined• LOEL mainly; rare NOEL • May not be reproducible• Dose distribution
![Page 6: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/6.jpg)
Design and Conduct of Oral Challenge Studies
![Page 7: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/7.jpg)
Subjects• Subpopulations: Adults vs children vs infants• Men and women, multiethnic• Particular concerns/issues:
Diagnosis for equivocal IgE or clinical history– Evidence of tolerance– Coexistant allergies (i.e. milk/soy)– Specific ingredients (i.e. hypoallergenic infant formulas)
• Exclusion of individuals:– Elevated food-specific IgE levels– Previous H/O anaphylaxis or unstable asthma– Self exclusion
![Page 8: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/8.jpg)
Test materials• Type of food material
– Various preparations per food• Ex: Peanut flour vs ground peanut vs peanut butter
Increased shelf-life for ease of administration
• Liquid vs solid (dried) food• Fresh vs processed • Raw vs cooked• Dose units (mg food vs mg protein vs mg/kg)
![Page 9: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/9.jpg)
Blinding• Foods – mask taste, smell, and texture
– Vehicles (i.e. Milk shakes, oatmeal, tapioca) GI effects; may not mask taste
– Capsules Delayed absorption; bypass oral cavity
• Protocol – mask subject and/or researcher– Open– Singled-blinded (SB)– Double-blinded (DB)
• Placebos –false positive “nocebo” responses
![Page 10: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/10.jpg)
Dose protocol
• Starting dose (X) varies (usually mg doses)• Time interval varies• Dose escalation of divided doses (usually 6 to 10) w/ placebos • Two to 10-fold dose increments Stop after objective symptom; some also record subjective symptoms Report eliciting discrete and/or cumulative dose
X 2X 4X 8X 16X 32X 64X 108X
15-60min
LOEL NOEL
4X
7X
Negative
Obj.symptom
Subj.symptom
Open Challenge
1-2 hrs
10g solid60g wet
![Page 11: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/11.jpg)
Other issues
• Clinic/office –experimental setting • Medications• Fasting• Clinical history of reactivity
– i.e. exercise, oral allergy syndrome
![Page 12: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/12.jpg)
Statistical endpoints • Sampled population
– Percentage that will react to challenge (i.e. food allergy diagnosis)
– Percentage to have a mild vs severe initial reaction• General allergic population
– Percentage that will or will not react to specific food concentration (s) during challenge
– Confidence levels for incidence of allergic reactions
![Page 13: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/13.jpg)
Incidence Confidence level 95% 99% 99.9%
1/10 = .1 *29 44 661/20 = .05 59 90 1351/50 = .02 149 228 3421/100 = .01 299 459 6881/200 = .005 598 919 13801/500 = .002 1497 2301 34511/1000 = .001 2995 4604 69051/2000 = .0005 5992 9210 138141/5000 = .0002 14978 23030 345401/10000 = .0001 29957 46060 69080
Sample size and confidence levels
*Basis for hypoallergenicity determination for infant formulas
}Number of individuals to be tested
![Page 14: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/14.jpg)
Evaluation/Interpretation of Challenge Study Data
![Page 15: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/15.jpg)
General interpretation • Grouping of data for population statistics
– Most studies not standardized* • Dose, blinding/testing materials, or interpretation of
clinical symptoms– All sensitive populations included?– Statistical power for confidence levels
• Should this include data from individuals nonreactive to oral challenge?
– What about foreign challenge study data?
*Standardization of protocols has been proposed; however, the bulk of currently available data is from non-standardized studies
![Page 16: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/16.jpg)
General interpretation
• Experimental exposure – non real-life
– False positives/ negatives– Difficult to predict reactions to future
exposures
![Page 17: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/17.jpg)
Subject sensitivity• Genetic heterogeneity of individuals
– Sensitization to different allergens within food– High variability in dose (million-fold) from least sensitive to most
sensitive
• Potential link with severity– Some studies suggest that the individuals most sensitive to low
doses also appear to have the most severe reactions– Sensitivity/severity may vary with food type
• Individual sensitivities may vary over time– Influenced by H/O asthma– Eating behaviors and other factors (exercise, alcohol, medications)
![Page 18: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/18.jpg)
Hypothetical Dose Response Curve* *Model adapted from J. Hourihane
Dose of Allergenic protein
Severe
Moderate
Mild
2 1 3 4
1- “Normal”
2- ?Unstable asthma, alcohol, exercise
3- ?Food matrix, antihistamines
4- ?Unidentified factors
![Page 19: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/19.jpg)
Evaluation of Clinical Responses
• Interpretation of eliciting dose– Subjective vs objective symptoms
• Reaction severity– Dose-response endpoints
![Page 20: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/20.jpg)
Allergic Response EndpointsSubjective Symptoms Objective Symptoms
Skin pruritus (Itching) Urticaria (hives), Eczema,Angioedema (swelling)
Nausea Vomiting, diarrhea Throat dryness/tightness Laryngeal swelling, Voice hoarseness,
stridor (inspiratory wheeze), CoughShortness of breath, chest pain Respiratory distress (i.e., breathing
rate), Wheezing
Feeling of faintness, dizziness Syncope (fainting), Hypotension (low blood pressure)
“Sense of impending doom” Shock (very low blood pressure), dysrhythmia (abnormal heart rhythm)
?Interpretation of: Fussiness/ behavior change (infants); Abdominal pain (infants); Skin flushing; Shortness of breath
![Page 21: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/21.jpg)
Subjective vs objective symptomsObjective symptoms
– Measurable indicator of allergic response– Many different endpoints possible, including anaphylaxis– Interpretation may vary among investigators
Subjective symptoms– May result from nonallergic causes; often not recorded– Often occur prior to objective signs– Early adverse events/ LOELs?
• Need to review challenge and placebo data
![Page 22: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/22.jpg)
Other eliciting dose considerations• Starting dose
– If response at this dose, cannot derive NOEL Common finding with many diagnostic challenges
– Is this the lowest eliciting dose?• Dose increments – 2 vs 10-fold • Time interval between doses
Some adverse reactions may be delayed > 60 min (i.e. eczema)
• Discrete vs cumulative dose How does this mimic true exposure?
![Page 23: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/23.jpg)
B cell T cell
Food /Protein
IgEAntibody
Mast cell/ Basophil
Sensitization
Elicitation
ALLERGY
Release of mediators, cytokines (Amplification mechanism)Rapidly progresses in severity
Unique toxicological
response
![Page 24: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/24.jpg)
Severity of allergic response is on a continuum
Subjective Objective Anaphylaxis Death
• Not a fixed response - early observed objective symptom may rapidly progress to something worse
• Degree of amplification varies - symptoms may not be reproducible on subsequent rechallenge
![Page 25: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/25.jpg)
Reaction Severity• Most studies only report actual symptom• Few document severity of challenge response
– Mild vs moderate vs severe– Should severe responses be interpreted differently?– Anxiety/stress; medications; asthma
• Potentiating/ mitigating factors for severity• Challenge stops after initial positive response• Not a true dose-response study for severity
– What is dose interval from mild to severe reaction?
![Page 26: Oral Challenge Studies: Purpose, Design and Evaluation](https://reader035.fdocuments.us/reader035/viewer/2022081603/56815cfe550346895dcafe4c/html5/thumbnails/26.jpg)
Conclusions• Oral food challenges provide data on:
– Clinical sensitivity to minimal eliciting doses– Reaction severity to initial dose
• Challenge data currently available for interpretation is not standardized among studies
• Current data pool may not include extremely sensitive population (with regards to severity)
• Challenges have proven value as a diagnostic tool but not as a tool for predicting reaction severity to future exposures